Alpha memo: resveratrol exercise cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Tighten Receipt 1's framing: explicitly state the supplied excerpt only describes study aims and design (n=64 Wistar rats, four groups, 12-week training, acute bout at 20 weeks) without a quantified IL-6 effect direction; remove or hedge the 'could attenuate' causal language.
2. Correct the group-count discrepancy in Receipt 1 description to match the source (four groups of 16, n=64) rather than six groups.
3. Soften the human-side characterization: since Receipt 2's abstract is truncated before the VO2max interaction is fully reported, label the finding as 'title-implied blunting not yet confirmed by the supplied abstract' rather than a 'negative/additive-null pattern,' and avoid implying a confirmed directional effect.
4. Consider whether the alpha sentence's 'indicating the same anchor may not travel cleanly across species' is too strong given both receipts have excerpt-level limitations; rephrase as a tentative cross-species hypothesis pending a powered human replication.

Major issues

• Receipt 1 does not supply the observed IL-6 result direction in the supplied excerpt; the memo hedges to 'designed/aimed to assess' but still presents it as evidence that resveratrol 'could attenuate acute-exercise inflammation,' which overstates what the receipt actually shows.
• Receipt 2's abstract is truncated mid-sentence ('Training increased VO2max') and the memo correctly notes the truncation, yet still leans on the title's 'blunts' framing to characterize the human finding as a 'negative/additive-null pattern' — this characterization is not fully supported by the supplied excerpt and should be more explicitly tentative or qualified.

Minor issues

• The alpha sentence frames Receipt 1 as designed to 'blunt inflammation-related factors,' but the receipt language is 'aimed to evaluate the effect...on inflammation-related factors' — the blunting is hypothesized, not demonstrated in the supplied excerpt.
• Receipt 1 cites 64 male Wistar rats divided into four groups of 16, but the memo states 'six groups, each consisting of 16' (six groups × 16 = 96, which contradicts the n=64). The memo should reflect the receipt's four-group structure.
• The 'why surprising' paragraph frames Receipt 1 as making resveratrol 'plausible' for attenuating inflammation; this causal implication should be hedged given the excerpt only describes study aims.
• The falsifier paragraph is well-constructed but could specify minimum detectable effect size or power to make the future-study requirement more actionable.

Reviewer note

The memo attempts a bounded cross-species contrast (rodent resveratrol + exercise vs. human RCT) and correctly identifies that one receipt is rodent inflammation-focused while the other is a small human VO2max trial. The framing is honest about truncation and confounds, and the falsifier paragraph is a genuine strength. However, two material issues push this to revise: (1) Receipt 1 is described using 'designed/aimed' language but the memo still presents resveratrol as plausibly attenuating inflammation, which slightly oversteps the supplied excerpt that only reports study aims; (2) Receipt 2's abstract truncation means the 'blunts' framing is borrowed from the title rather than confirmed by the supplied excerpt, yet the memo characterizes it as a 'negative/additive-null pattern.' There is also an internal group-count error (memo says six groups of 16, source says four groups of 16, n=64). With these tightened — corrected group count, hedged Receipt 1 framing, and explicit acknowledgment that the human blunting is title-implied rather than excerpt-confirmed — the memo would meet the accept threshold. The core analytic move (cross-species contrast with explicit caveats) is sound and worth preserving.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis